nusinersen sodium - Profile

What are the generic drug sources for nusinersen sodium and what is the scope of freedom to operate?

Nusinersen sodium is the generic ingredient in one branded drug marketed by Biogen and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nusinersen sodium has one hundred and seven patent family members in twenty-eight countries.

Summary for nusinersen sodium

International Patents:	107
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for nusinersen sodium

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for nusinersen sodium

Dosage:

SOLUTION;INTRATHECAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for NUSINERSEN SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPINRAZA	Intrathecal Solution	nusinersen sodium	12 mg/5 mL	209531	1	2026-03-10

US Patents and Regulatory Information for nusinersen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes

Expired US Patents for nusinersen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016

International Patents for nusinersen sodium

Country	Patent Number	Title	Estimated Expiration
Brazil	112017004056	composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
Chile	2017000594	Composiciones y métodos para detección de proteína smn en un sujeto y tratamiento de un sujeto
Chile	2019000447	Composiciones y métodos para detección de proteína smn en un sujeto y tratamiento de un sujeto. (divisional solicitud 201700594)
Colombia	2017002400	Composiciones y métodos para detección de proteína smn en un sujeto

Supplementary Protection Certificates for nusinersen sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2548560	PA2017037,C2548560	Lithuania		PRODUCT NAME: NUSINERSENAS ARBA JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1188/001 20170530
2548560	57/2017	Austria		PRODUCT NAME: NUSINERSEN UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/17/1188 MITTEILUNG 20170601
2548560	C 2017 045	Romania		PRODUCT NAME: NUSINERSEN SAU SARURI ALE ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1188; DATE OF NATIONAL AUTHORISATION: 20170530; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1188; DATE OF FIRST AUTHORISATION IN EEA: 20170530
2548560	PA2017037	Lithuania		PRODUCT NAME: NUSINERSENAS ARBA JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1188/001 20170530

An In-Depth Analysis of Nusinersen Sodium: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Nusinersen sodium (brand name: Spinraza) is a neuromuscular disorder drug developed by Biogen for the treatment of spinal muscular atrophy (SMA). As the first approved antisense oligonucleotide therapy for SMA, it has reshaped market expectations in rare disease therapeutics. This report presents a comprehensive review of its investment potential, market landscape, and projected financial performance, incorporating recent developments from regulatory authorities, payer policies, and industry competitors.

1. Investment Scenario Overview

1.1 Market Size and Revenue Potential

• Global SMA Treatment Market: Projected to reach approximately $4.8 billion by 2027 (Fortune Business Insights, 2022).
• Nusinersen's Market Share (2022-2027): Estimated to retain dominant position, capturing ~70-80% of SMA therapeutics revenue.
• Pricing: In the U.S., Spinraza’s initial list price is approximately $750,000/year per patient; total revenues depend on patient numbers and reimbursement landscapes.

1.2 Investment Highlights

Factor	Details	Source/Implication
Patent Portfolio	Key composition patents extend to 2027-2035	Validity supports exclusivity window
FDA Approval	First-approved SMA therapy (2016); expanded indications	Market entry advantages, regulatory data confidence
Reimbursement	Medicare, Medicaid, private payers cover Spinraza	Enhances market penetration; reduces price barriers
Pipeline Development	Companion therapies and gene therapies advancing	Potential to replace or complement Spinraza

1.3 Risks and Challenges

Risk Factor	Impact	Mitigation Strategies
Pricing and Access	Reimbursement constraints could limit revenue	Engage with payers, demonstrate cost-effectiveness
Competitive Entries	New therapies (e.g., Zolgensma, Risdiplam)	Innovate combination strategies, expand indications
Regulatory Hurdles	Delays in approval or expanded labels	Robust clinical development programs

Conclusion: The investment opportunity in nusinersen hinges on sustained prognosis for SMA patient growth, payer acceptance, and competitive positioning against emerging therapies.

2. Market Dynamics

2.1 Key Players and Competitive Landscape

Company	Product	Mechanism	Market Share (2022)	Notable Developments
Biogen	Spinraza (nusinersen)	ASO (antisense oligonucleotide)	~65%	Ongoing label expansions
Novartis	Zolgensma (onasemnogene abeparvovec)	Gene therapy	~20%	Single-dose approval, high pricing (~$2.1 million)
Roche	Evrysdi (risdiplam)	Small molecule SMN2 splicing modifier	~15%	Oral alternative, expanding indications

Market share estimates are based on data from EvaluatePharma (2022).

2.2 Adoption and Reimbursement Policies

• United States: CMS coverage decisions include coverage for SMA patients under Medicare and Medicaid.
• Europe: National health authorities increasingly reimburse Spinraza, with some regional disparities.
• Price Negotiations: Governments initiate pricing reforms; payers push for value-based agreements.

2.3 Pricing and Payment Models

Model	Description	Examples	Implication
One-time payment	Up-front or single-dose payment	Zolgensma	High upfront cash flow, risk of non-maintenance
Annually recurring	Yearly treatment fee	Spinraza	Revenue stability, affordability challenges
Outcome-based agreements	Payment tied to patient outcomes	Some US programs	Risk-sharing, incentivizes efficacy

2.4 Regulatory and Policy Trends

• FDA & EMA: Favor accelerated approvals for rare diseases; emphasize real-world evidence.
• Pricing pressures: Increasing emphasis on affordability; some European countries negotiate volume discounts.
• Orphan Drug Designation: Extends exclusivity, provides tax credits, and grants exclusivity periods.

3. Financial Trajectory

3.1 Revenue Projections (2023-2027)

Year	Estimated Patients	Approximate Revenue (USD millions)	Notes
2023	10,000	$7,500	Market stabilization, ongoing expansion
2024	12,000	$9,000	Increased uptake, new indications
2025	15,000	$11,250	Entry of new competitors, expanded labeling
2026	18,000	$13,500	Market maturity, potential pricing adjustments
2027	20,000	$15,000	Peak market penetration

Assumptions: steady global diagnosis rates, increased payer coverage, and successful indication expansions.

3.2 Cost Structure Analysis

Cost Component	Approximate % of Revenue	Notes
R&D	15-20%	Continual investment, pipeline development
Manufacturing	20-25%	Scale-up efficiencies, supply chain risks
Commercial Operations	15-20%	Market access, sales teams
Legal/IP & Regulatory	5-10%	Patent defense, submissions

3.3 Profitability Outlook

• Gross margins expected at ~70-80%.
• EBITDA margins projected at ~40-50% in mature phases, considering discounts and reimbursement variations.

3.4 Valuation Metrics

Metric	Typical Range	Comments
Price-to-Sales (P/S)	8-12x	Reflects high R&D intensity and growth potential
Market Capitalization	Based on revenue estimates	Biogen's valuation largely driven by Spinraza's flagship status

4. Comparison with Competitors

Aspect	Spinraza (Nusinersen)	Zolgensma	Evrysdi (Risdiplam)
Mechanism	ASO	Gene therapy	Small molecule
Approval Year	2016	2019	2020
Pricing	~$750,000/year	~$2.1 million single dose	~$340,000/year
Dosing	Intrathecal injections	Single infusion	Oral daily
Market Share (2022)	65%	20%	15%

Note: Zolgensma's high price is offset by single-dose administration, and Evrysdi's oral route offers regimen convenience.

5. Deep Dive into Market Drivers and Challenges

5.1 Drivers

• Increase in SMA Diagnoses: Newborn screening initiatives lead to earlier detection.
• Expanding Indications: Use in later disease stages and wider age groups.
• Technological Advances: Enhancements in oligonucleotide chemistry improve efficacy and safety.
• Payer Acceptance: Growing evidence of cost-effectiveness supports broader reimbursement.

5.2 Challenges

• Pricing and Reimbursement Pressure: Governments push for value-driven payment models.
• Competition from Gene and Small Molecule Therapies: Innovation trajectory may impact long-term market share.
• Manufacturing Complexities: Supply chain sustainability, especially with low-temperature storage requirements.

6. Regulatory and Policy Outlook

Policy/Trend	Impact on Nusinersen	Strategic Implication
Price Negotiations	Potential discounts or value-based pricing	Build early payer engagement strategies
Expanded Approvals	Broader patient access	Invest in clinical trials for new indications
Orphan Drug Policies	Longer exclusivity	Protect market share against generics or biosimilars

7. Key Takeaways

• Market Dominance: Nusinersen's first-mover advantage and regulatory approval provide a strong foundation for sustained revenue, though competition is intensifying.
• Revenue Forecasts: Expect a compound annual growth rate (CAGR) of approximately 10-12% from 2023-2027, driven by diagnosis rates and label expansion.
• Pricing Strategy: High price points necessitate ongoing payer engagement and demonstration of cost-effectiveness.
• R&D and Pipeline Criticality: Continuous innovation and indication expansion are vital to maintain competitive edge.
• Regulatory Landscape: Monitoring policy changes and reimbursement pathways remains essential for investment planning.

8. Conclusion

Nusinersen sodium represents a high-value investment in the rare disease space, supported by a strong clinical profile, regulatory approvals, and a relatively secured patent portfolio. However, its long-term financial trajectory depends heavily on market expansion, competitive positioning, and healthcare reimbursement dynamics. Stakeholders should closely track advancements in gene therapy, pricing reforms, and healthcare policies to optimize investment outcomes.

---

9. FAQs

Q1: What are the primary drivers of nusinersen’s market growth?
A1: Increased SMA diagnosis through newborn screening, broader approved indications, technological improvements, and payer acceptance underpin growth prospects.

Q2: How does competition from gene therapies impact nusinersen?
A2: While gene therapies like Zolgensma offer single-dose treatment, their high upfront cost and eligibility constraints contrast with nusinersen’s ongoing dosing, creating a complementary or competitive dynamic.

Q3: What are the major reimbursement challenges for nusinersen?
A3: Payers are increasingly demanding value-based pricing and outcome-driven reimbursement schemes, potentially affecting revenue stability.

Q4: How do price negotiations influence long-term profitability?
A4: Negotiations and potential discounts can reduce revenue per patient but may expand market access and volume, balancing profitability.

Q5: What is the outlook for nusinersen's patent protection?
A5: Patents currently extend into the late 2020s and early 2030s; expiration could open the market to generics or biosimilars unless extended or supplemented by new patents.

---

References

1. Fortune Business Insights. (2022). Global SMA Treatment Market Size, Share & Industry Analysis.
2. EvaluatePharma. (2022). Top Pharmaceutical Markets & Competitors.
3. FDA. (2016). Approval Letter for Spinraza.
4. Biogen. (2022). Spinraza Regulatory and Commercial Data.
5. European Medicines Agency. (2020). Evaluation of Evrysdi.

(End of Report)